Search the Newsreel

NeoGenomics (NEO) Launches PTEN IHC CDx, Does The Valuation Still Look Full?

NeoGenomics (NEO) has launched a new PTEN IHC CDx diagnostic following FDA approval, contributing to significant recent stock price appreciation. While the company is considered 3.7% undervalued by some metrics, with a fair value estimate of $15.06, its current price-to-sales ratio of 2.5x is …

Number of shareholders of Bionano Genomics, Inc. – GETTEX:2Y3

This article displays information regarding the number of shareholders of Bionano Genomics, Inc. (GETTEX:2Y3) on TradingView. It provides a snapshot of the company's market status, indicating that the market is currently closed with no trades. The page is part of the extensive financial data …

NGMS stock holds its ground after Neogenomics revenue trends improve

Neogenomics, Inc. (NGMS) reported improved financial results, with 2024 revenue reaching $169.0 million, a 12.5% increase from the previous year, and a significant improvement in adjusted EBITDA from a $25.8 million loss in 2023 to a $3.9 million loss in 2024. This performance, driven …

PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?

This article analyzes Precipio, Inc. (PRPO) and NeoGenomics, Inc. (NEO), two oncology diagnostics companies, to determine which offers a better investment opportunity. While both operate in the cancer diagnostics market, NeoGenomics is presented as the stronger buy due to its broader scale, diversified growth …

ETFs Investing in 10x Genomics Inc Class A Stocks

This article lists the various Exchange Traded Funds (ETFs) that hold 10x Genomics Inc Class A (TXG) stocks. It provides a detailed table including fund names, market value of TXG holdings, weight in the fund, issuer, management style, expense ratio, AUM, price, change, relative …

TXG Stock Rallies As Wall Street Hikes Price Targets

10x Genomics Inc. (TXG) stock has rallied by 9.43% due to strong demand for its single-cell platform and increased price targets from Wall Street analysts. Barclays, Morgan Stanley, and Citi have all raised their price targets for TXG, indicating improved sentiment for life science …

A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack

Edding Genor Group Announces Milestone Licensing and Acquisition Updates for GB261 with Candid Therapeutics and UCB – Minichart

NeoGenomics (NEO) Releases Q1 2026 Earnings: Revenue Up 11.1% but EPS Misses

NeoGenomics’s (NASDAQ:NEO) Q1 CY2026: Beats On Revenue

NeoGenomics Earnings: What To Look For From NEO

NeoGenomics (NEO) Q4 2024 Earnings Transcript

A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack

NEOGENOMICS ($NEO) Releases Q4 2025 Earnings

NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates

NEOGENOMICS Earnings Results: $NEO Reports Quarterly Earnings | NEO Stock News

Mega Genomics Limited (6667.HK) Stock Price, News, Quote & History

Technical Analysis of Edding Genor Group Holdings Limited (HKEX:6998)